		Table of Contents	Page No.
Abstr	act		i-iii
Declaration by the Candidate			iv
Certificate of the Principal Supervisor			v
Acknowledgement			vi-vii
Table	e of Contents		viii-xii
List o	of Figures		xiii-xv
List o	of Tables		xvi-xvii
List o	of Keywords		xviii
List o	of Symbols a	nd Abbreviations	xix-xxiii
Chap	oter 1: Intro	oduction and Review of Literature	1-22
1.1	Venomous s	snakes and snakebite	1-3
1.2	Bungarus fa	esciatus	3-6
	1.2.1	Distribution of <i>B. fasciatus</i>	4-5
	1.2.2	Morphology of B. fasciatus	5
	1.2.3	Habitat and Ecology of B. fasciatus	5-6
	1.2.4	Food habits of <i>B. fasciatus</i>	6
1.3	B. fasciatus	's pathophysiological landscape	6-8
1.4	Antivenom	therapy: Present scenario and limitations	8-12
1.5	Alternative	approaches to antivenom therapy	13-15
1.6	<i>B. fasci</i> atus	venom variation and antivenom cross-reactivity	15-19
	1.6.1	<i>B. fasciatus</i> venom composition and intra-species venom variation	15-19
	1.6.2	B. fasciatus venom variation and antivenom cross-reactivity	19-20
1.7	Need for th	e study	21
1.8	Research H	ypothesis	21
1.9	Aim of the study		
1.10	Objectives	of the study	21
1.11	Experiment	al approach	22
-		lysis of crude <i>Bungarus fasciatus</i> venoms from different ations of Eastern and North-East India	23-44

2.1	Introduction			23-24
2.2	Materials			25-31
	2.2.1	Snake ver	ioms	25
	2.2.2	Chemical	s and reagents	25
	2.2.3	Columns		26
2.3	Methods			26-31
	2.3.1	Protein e	stimation	26
	2.3.2	Sodium d (SDS-PA	odecyl sulphate-Polyacrylamide gel electrophoresis GE)	26
	2.3.3	Reversed (RP-HPL	phase- High Performance Liquid Chromatography C)	27
	2.3.4	Phosphol	ipase A ₂ activity	27-28
	2.3.5	Proteolyt	ic activity	28-29
	2.3.6	Hemolyti	c activity	29-30
	2.3.7	Coagulati	ion activity	30-31
	2.3.8	Statistica	l analysis	31
2.4	Results			31-40
	2.4.1	Quantita	ative and qualitative analysis of crude venom profile	31-34
		2.4.1.1	Protein estimation of crude venoms	31-32
		2.4.1.2	Gel electrophoresis of crude B. fasciatus venoms	32-33
		2.4.1.3	RP-HPLC profiling of crude B. fasciatus venoms	33-34
	2.4.2	Compar	ative biochemical analysis of crude venoms	34-40
		2.4.2.1	Phospholipase A ₂ activity of crude venoms	34-36
		2.4.2.2	Proteolytic activity of crude venoms	36-37
		2.4.2.3	Hemolytic activity of crude venoms	37-38
		2.4.2.4	Coagulation activity of crude venoms	39-40
2.5	Discussion			40-44
2.6	Conclusion			44
Cha	pter 3: Cross	-reactivity	of Indian polyvalent antivenom against <i>Bungarus</i>	45-61

Chapter 3: Cross-reactivity of Indian polyvalent antivenom against Bungarus45-61fasciatus venoms from different geographical locations of Eastern and North-East India

3.1	Introduction	45-46
3.2	Materials	47-48

	3.2.1	Snake venoms	47
	3.2.2	Indian polyvalent antivenom	47
	3.2.3	Chemicals and reagents	47-48
	3.2.4	Chromatographic Columns	48
3.3	Methods		48-51
	3.3.1	F(ab') ₂ content and SDS-PAGE analysis of Indian polyvalent antivenom	48-49
	3.3.2	Dialysis of polyvalent antivenom	49
	3.3.3	Western blot analysis	49-50
	3.3.4	Second-generation antivenomics	50-51
3.4	Results		51-56
	3.4.1	Comparative analysis of Indian polyvalent antivenom	52-53
	3.4.2	Immunochemical analysis of antivenom using Western blotting	53-54
	3.4.3	Immunodepletion analysis using Second-generation antivenomics	54-57
3.5	Discussion		57-61
3.6	Conclusion		61
Bun	-	ion and identification of poorly-immunodepleted proteins of as venom from North-East India using third-generation	61-82
4.1	Introduction		62-65
4.2	Materials		64
	4.2.1	Snake venoms	64
	4.2.2	Indian polyvalent antivenom	64
	4.2.3	Chemicals and reagents	64
	4.2.4	Chromatographic Columns	65
4.3	Methods		65-69
	4.3.1	3G antivenomics	65-67
	4.3.2	Gel electrophoresis and Western Blotting	67
	4.3.3	Identification of proteins by ESI-LC-MS/MS	68-69
4.4	Results		69-79

	4.4.1	Maximum binding capability of antivenom targeting <i>B</i> . <i>fasciatus</i> venom from Aizawl (Mizoram)	69-71
	4.4.2	Maximum binding capability of antivenom targeting <i>B</i> . <i>fasciatus</i> venom from Guwahati (Assam)	72-74
	4.4.3	Estimation of antivenom vials required to immunocapture all venom proteins in <i>B. fasciatus</i> envenomated victim and its associated cost	74-75
	4.4.4	SDS-PAGE and Western Blotting of poorly-immunodepleted peaks	75-76
	4.4.5	Identification of proteins by Liquid chromatography-tandem mass spectrometry	76-79
4.5	Discussion		80-83
4.6	Conclusion		83
	-	acterization of poorly-immunodepleted peaks and identified om <i>B. fasciatus</i> venom of Assam, India	84-108
5.1	Introductio	n	84-85
5.2	Methods		86-89
	5.2.1	Characterization of poorly-immunodepleted PLA ₂ proteins	86
		5.2.1.1 PLA ₂ activity	86
		5.2.1.2 Anticoagulant activity	86
	5.2.2	Neutralization of in vitro enzymatic activities by Indian polyvalent antivenom	86
	5.2.3	Multiple sequence alignment	86-87
	5.2.4	Phylogenetic tree analysis	87
	5.2.5	Tertiary structure prediction using Homology modelling and its validation	87-88
	5.2.6	B-cell epitope prediction of identified PLA ₂ enzymes	88
	5.2.7	Surface cavity search	88
	5.2.8	Statistical analysis	88
5.3	Results	-	89-102
	5.3.1	Characterization of poorly-immunodepleted PLA ₂ proteins	89-91
		5.3.1.1 PLA ₂ activity -1	89
		5.3.1.2 Anticoagulant activity	89-90
	5.3.2	Neutralization of in vitro enzymatic activities	90-91
		,	

	5.3.3 Multiple sequence alignment			
	5.3.4 Phylogenetic tree analysis			93-94
	5.3.5 Tertiary structure modelling and validation of identified PLA ₂ enzymes			94-96
	5.3.6	B-cell e	pitope prediction of identified PLA ₂ enzymes	97-101
	5.3.7	Surface	cavity search in identified PLA ₂ enzymes	102-103
5.4	Discussion	l		103-108
5.5	Conclusion	1		108
Chap	oter 6: Criti	cal Discu	ssion and Future Prospects	109-115
6.1 Critical Discussion				109-112
	6.1.1	Steps to	consider before antivenom manufacturing	109-110
	6.1.2 Region-specific antivenom6.1.3 Alternate approaches currently explored			110
				111
		6.1.3.1	Single-chain variable fragments (scFvs)	111
		6.1.3.2	Single-domain antibodies (sdAbs)	111
	6.1.4	Next ger	neration antivenom	111-113
		6.1.4.1	Monoclonal antibodies	112
		6.1.4.2	Human monoclonal antibodies	112-113
		6.1.4.3	Protein based ADDomer nanoparticles (The ADDovenom project)	113-114
6.2 F	6.2 Future prospects of this study			114-115
Bibli	ography			116-149
List	of publicatio	ns		150
Арре	Appendix I: Permissions and Approvals			xxiv
Appendix II: Reprints of Publications			XXV	